Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249799 | 1.00 | CES1 (0.43) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| SCHEMBL249800 | 1.00 | CES1 (0.43) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| SCHEMBL15895048 | 0.88 | CES1 (0.42) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| SCHEMBL236357 | 0.87 | CES1 (0.47) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| SCHEMBL246914 | 0.87 | CES1 (0.47) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| SCHEMBL236358 | 0.87 | CES1 (0.47) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| Hydrochloric Acid SCHEMBL8829227 | 0.85 | CES1 (0.46) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| Hydrochloric Acid SCHEMBL4926039 | 0.85 | CES1 (0.46) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| Hydrochloric Acid SCHEMBL5595770 | 0.85 | CES1 (0.46) | CES1KCNN4ENPP2CYP1A2NR1H2 | |
| SCHEMBL7436744 | 0.84 | CES1 (0.44) | CES1KCNN4ENPP2CYP1A2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 679 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760750-B1 | Process for preparing levoketoconazole | NURAY CHEMICALS PRIVATE LIMITED (IN) | 2023-09-19 | — | — | US | claimed |
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-1023284-B1 | ANTI-VIRAL PHARMACEUTICAL COMPOSITIONS CONTAINING SATURATED 1,2-DITHIAHETEROCYCLIC COMPOUNDS | US GOV HEALTH & HUMAN SERV (US) | 2005-11-23 | — | — | EP | claimed |
| EP-1023284-A2 | ANTI-VIRAL PHARMACEUTICAL COMPOSITIONS CONTAINING SATURATED 1,2-DITHIAHETEROCYCLIC COMPOUNDS AND USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-08-02 | — | — | EP | claimed |
| US-6046228-A | INCLUDE 1,2-DITHIANE AND 1,2 DITHIOLANE COMPOUNDS, THE RING SULFUR ATOMS MAY BE PRESENT IN THE SULFUR OXIDE OR SULFONE STATE, USEFUL FOR INHIBITING RETROVIRUS REPLICATION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-04-04 | — | — | US | claimed |
| WO-1998001440-A9 | ANTI-VIRAL PHARMACEUTICAL COMPOSITIONS CONTAINING SATURATED 1,2-DITHIAHETEROCYCLIC COMPOUNDS AND USES THEREOF | — | 1998-07-16 | — | — | WO | claimed |
| WO-1998001440-A2 | ANTI-VIRAL PHARMACEUTICAL COMPOSITIONS CONTAINING SATURATED 1,2-DITHIAHETEROCYCLIC COMPOUNDS AND USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-15 | — | — | WO | claimed |
| EP-4741399-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | President And Fellows Of Harvard College (US) | 2026-05-13 | — | — | EP | disclosed |
| CN-122011012-A | (S) -tert-butyl ((2-methyl-7- (trimethylsilyl) hept-6-alkyne-1-yl) oxy) diphenyl silane and synthesis method and application thereof | 山东省农业科学院 | 2026-05-12 | — | — | CN | disclosed |
| EP-4640279-A2 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2025-10-29 | — | — | EP | disclosed |
| EP-4634184-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | Crossfire Oncology Holding B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| EP-3664799-B1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | HARVARD COLLEGE (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4356969-B1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2025-07-09 | — | — | EP | disclosed |
| EP-0362816-A1 | Cyclopenteneheptanoic acid derivatives and method of preparation thereof | G.D. Searle & Co. (US) | 1990-04-11 | — | — | EP | disclosed |
| EP-0358154-A2 | Novel cyclobutane derivative and process for producing same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1990-03-14 | — | — | EP | disclosed |
| US-4898977-A | Processes for the preparation of 5-amino-4-hydroxyvaleric acid derivatives | CIBA-GEIGY CORPORATION (US) | 1990-02-06 | — | — | US | disclosed |
| EP-0353053-A2 | Catalytic process for producing optically active alpha-hydroxycarboxylates | Takasago International Corporation (JP) | 1990-01-31 | — | — | EP | disclosed |
| US-4895979-A | HYDROGENATION OF GAMMA-HALO-BETA-KETO ESTER, RUTHENIUM-OPTICALLY ACTIVE PHOSPHINE CATALYST, QUATERNIZATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1990-01-23 | — | — | US | disclosed |
| EP-0319471-A2 | Resolution process | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | disclosed |
| WO-1988000190-A1 | OPTICALLY ACTIVE DERIVATIVES OF GLYCIDOL | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1988-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | NRAS, BRAF, KRAS | CES1 3869/4885KCNN4 3072/4885ENPP2 604/4885 |
| US-11760750-B1 | Process for preparing levoketoconazole | KHK, KYAT3, PLK3 | CES1 558/4885KCNN4 3027/4885ENPP2 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.